Rosiglitazone is a hypoglycemic drug developed by GS, and the revalent compounds are disclosed in European Patent EP 306228.
Rosiglitazone hydrochloride has better stability than rosiglitazone maleate, and is very suitable for application in the manufacture of common pharmaceutical preparations. It is a thiazolidinedione antidiabetic drug, which can effectively control blood sugar by improving insulin sensitivity.
rosiglitazone is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the ppar receptors in fat cells.
